Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  -1.10 -0.9% 120.80 1,404,425 16:35:22
Bid Price Offer Price High Price Low Price Open Price
120.30 120.70 122.00 119.30 121.90
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 473.23 -126.54 -14.63 887
Last Trade Time Trade Type Trade Size Trade Price Currency
18:00:46 O 30,697 121.003 GBX

Indivior (INDV) Latest News

More Indivior News
Indivior Investors    Indivior Takeover Rumours

Indivior (INDV) Discussions and Chat

Indivior Forums and Chat

Date Time Title Posts
02/3/202114:50INDIVIOR THE PILL WITH NO CHEERS OR BEERS3,146
09/3/202010:34RB. de-merger 548
11/7/201907:29Johnson & Johnson court case oklahoma6
03/5/201909:16Judgement against insys2
31/7/201812:45Indivior (INDV) IP Battle Status -

Add a New Thread

Indivior (INDV) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-03-05 18:00:54121.0030,69737,144.29O
2021-03-05 18:00:54121.0060,31772,985.38O
2021-03-05 18:00:06121.093,9874,827.66O
2021-03-05 17:25:04120.801,4831,791.46O
2021-03-05 16:42:24120.8011,24913,588.79O
View all Indivior trades in real-time

Indivior (INDV) Top Chat Posts

DateSubject
05/3/2021
08:20
Indivior Daily Update: Indivior Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 121.90p.
Indivior Plc has a 4 week average price of 119.30p and a 12 week average price of 93.70p.
The 1 year high share price is 165.10p while the 1 year low share price is currently 35.88p.
There are currently 734,086,392 shares in issue and the average daily traded volume is 1,626,029 shares. The market capitalisation of Indivior Plc is £886,776,361.54.
18/1/2021
19:19
timmy11: RE: Interesting analysis of Indivior (Litigation Investor)Today 14:44 This Report is excellent, very comprehensive & well worth the read. Some of the points it makes are as follows: "Suboxone sales have remained resilient in the face of generic competition (and even saw modest growth in the most recent quarter, Q3 2020) Sublocade unit growth is accelerating (growing 15% in Q3 2020 over Q2 2020) Sublocade sales should easily exceed management guidance A competitive entrant, Brixadi, has been delayed (likely, >12 months) as Braeburn (Brixadi's license holder in the U.S.) received a complete response letter from the FDA. Based on our projections for Sublocade sales growth it is easy to see a near term value for Indivior ordinary shares of 200p." It also states that the Reckitt claim is a " baseless preliminary claim filed by Indivior’s former parent company" that is "procedurally defective and substantively precluded due to Reckitt’s alleged acts of fraud or dishonesty." I agree with the Report and believe that the Reckitt claim was a crude attempt to try & stifle a much stronger claim by INDV on Reckitt. This is also the view taken by the Report. It goes on to forecast an share price of £5 for INDV by 2025 based on INDV's market leading position and on the growth of SUBLOCADE as well as other products supplied by INDV using their monthly injectable technology such as PERSERIS designed to combat Schizophrenia. INDV's share price should continue to firm from here on the run-up to releasing its full year results on 18th February.
15/1/2021
17:52
grupo guitarlumber: Indivior is the biggest FTSE 250 gainer today. Would I buy it now? Manika Premsingh | Friday, 15th January, 2021 Business development to success and FTSE 100 250 350 growth concept. The FTSE 250 opioid addiction treatment provider Indivior (LSE: INDV) is the biggest index gainer today as I write. Its share price is up 9%, continuing its recovery after a sharp fall in late November. Why the share price rose INDV’s better-than-expected financial results are the clear reason for the uptick in share price. It now expects revenue to be at least $25m higher than it had expected earlier for the full year. It also expects expenses to be lower, resulting in an improved income forecast. What’s next for the INDV share price I reckon that the latest news will provide continued impetus for INDV’s share price. It’s now at 115p, up from the sub-100p levels it was at before the last week of December. The big decline started in late November, when it crashed 30% in a day following news that its former parent company — Reckitt Benckiser — had filed a £1bn claim on it. Even now the share price is still much lower than its 131p levels at the time. But at least it’s now closer than ever to getting back there. When I last wrote about Indivior, after its share price fall, my sense was that its share price would be dependent more on its own performance than anything else. If the share price reaction to its latest results is anything to go by, it only proves the point I was making at the time. If its performance remains consistent, I reckon that its share price can climb up further. This is especially so in today’s bullish market, where investors are rewarding companies that are performing well. Battling the opioid crisis Moreover, the seriousness of the opioid crisis is big and rising, an issue that Indivior is well placed to address. According to the World Health Organisation, globally 0.5m deaths are caused by drug use every year, of which 70% are opioid-related. Moreover, between 2010 and 2018, the number of people dying of opioid overdose in the US increased by 120%. Past problems still haunt Despite this, as an investor I’m cautious because of INDV’s problems from the recent past, which include accusations of mis-selling and resulted in its former CEO being imprisoned. Almost two months after I wrote about INDV, it indeed appears to have put the episode behind it. It has also said that Reckitt Benckiser’s claim is without merit. Further, its financials had suffered quite the blow in the first nine months of 2020, with a sharp decline in revenue. The latest numbers, then, are a surprise development and not one that reflects the inherent, ongoing strength of the company. I think the INDV stock looks much better after its results than it did two months ago when it was far more in the thick of a crisis. It could continue to see improvements from here. But I really want to see some more predictability to its financials before buying the stock. Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned.
29/12/2020
17:15
the grumpy old men: Share Price: 103.40 Change: 0.70 (0.68%)
23/12/2020
09:03
the grumpy old men: Share Price: 95.35 Change: 0.80 (0.85%)
13/12/2020
16:02
lindowcross: Looks like the wording of the clause is not yet in the public domain. It's difficult to gauge the effect on Indivior without knowing the precise wording of the indemnity clause and the whole wording of the contract. An indemnity is a primary obligation, so it's an express obligation to compensate someone for loss or damage and is independent of the obligations of the party, that is, INDV, whose promises or contractual terms are being reinforced by the provision of the indemnity. The indemnity does not depend on having to prove a breach of a contractual obligation. So what did INDV promise to do or not do? And did their lawyers protect them at the time with reasonable safeguards in the drafting of the contract? It looks like RB has filed the Claim Form which just sets out a brief summary of the claim and the full Points of Claim will come within the next 3-4 months setting out exactly why it is they claim INDV is in breach of the indemnity and so owes them cash. Perhaps directors of RB were advised they had no option but to bring the claim due to their legal duty to shareholders.
27/11/2020
15:55
waldron: the motely fool Why did the Indivior share price crash 40% on Friday? Alan Oscroft | Friday, 27th November, 2020 | Drug manufacturer Indivior (LSE: INDV) had been soaring in 2020. In fact, as of market close Thursday, the Indivior share price had more than trebled so far this year. But that came to a crunching halt Friday with a whopping 40% crash. Indivior is still ahead more than 100% year-to-date, but what’s happened? Indivior was spun out of Reckitt Benckiser in 2014. And news emerged Friday that its parent has filed a $1bn lawsuit against it. The claim was, apparently, filed on 13 November. It involves an indemnity agreement between the two companies, signed at the time of their parting. 5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit! According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air… And if you click here we’ll show you something that could be key to unlocking 5G’s full potential... In its announcement, Indivior said: “The claim has not been served on the company and the company does not have any further details at this time. The company will assess with its advisors the background and merits to the case and will provide an update in due course.“ More legal pressure for Indivior So we don’t have the details yet. But it’s telling that Indivior has been facing lawsuits related to its opioid dependency treatment Suboxone. The opioid dependency scandal is huge in the US. But it had seemed the matter was resolved after a previous US court case. On 13 November, Indivior told us that “a United States federal court in the Western District of Virginia has approved the agreement between the group and the U.S. Department of Justice and other government agencies that was announced on July 24. The court has also dismissed all charges that were returned by a grand jury in April 2019.” The company added that it “is pleased to put this matter behind it and move forward in a manner that provides certainty to its business.” That certainty has now been shattered. Thought it was all over? As part of the earlier agreement, Indivior had to pay $600m. Prior to that, in October, former CEO Shaun Thaxter had received a six-month jail sentence on charges relating to misrepresentation of the safety of Suboxone. Reckitt Benckiser had had to stump up $1,4bn to try to put it all behind it. And if that wasn’t enough, Indivior has been trying to fight off generic competitors who claim its patent has expired. That’s quite a story for a FTSE 250 company that, by Friday afternoon at least, has still seen its share price double in 2020. But what now? A tense wait Well, we’ll clearly need to wait and find out the details of the Reckitt Benckiser lawsuit. And how nice of Indivior to release the news on a Friday, to give investors time to stew over the weekend with no real hope of further information. Perhaps obviously, I wouldn’t buy now. But I generally wouldn’t invest in a company that’s been facing big legal problems anyway. And definitely not one connected with the US opioid dependency drama.
23/11/2020
11:47
adrian j boris: (INDV) London Stock Exchange Share Price: 131.50 Bid: 131.30 Ask: 131.60 Change: 0.40 (0.31%)
14/11/2020
04:57
ariane: HOME > Latest > Indivior sinks as settlement confirmed Indivior sinks as settlement confirmed By Master Investor 13 November 2020 0 mins. to read Indivior sinks as settlement confirmed FTSE 250 pharmaceuticals firm Indivior (LON:INDV) saw its share price drop by 1.79% to 120.80p (as of 11:55 GMT) after a US federal court approved the agreement between the firm and the Department of Justice. Under the terms of the agreement, the company will pay $600 million over seven years and all charges brought by grand jury due to a subsidiary’s false statements will be dismissed. Management said they were pleased to put this matter behind them and to allow the company to move ahead with certainty.
02/11/2020
16:49
waldron: SURPRISED AT THE SPREAD Indivior (INDV) London Stock Exchange Share Price is delayed by 15 minutes Share Price: 107.20 Bid: 121.00 Ask: 98.25 Change: -3.10 (-2.81%) Spread: -22.75 (-18.80%)
06/6/2020
07:37
gibbs1: If we accept that the current INDV share price is valued realistcally until of course the court case is solved then the INVVY ADR in opinion seems a little overvalued Begs the question DO THEY KNOW SOMETHING WE DO NOT KNOW ME THINKS NO
Indivior share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
INDV
Indivior
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210306 00:15:37